The PARI LC PLUS® has been trusted by pharmaceutical companies in clinical trials to prove safety and efficacy of new medications for more than 30 years. Considered the “GOLD Standard” in nebulizer therapy for the treatment of diseases such as asthma, COPD and Cystic Fibrosis, its integrated valve system maximizes drug delivery upon inhalation and minimizes drug loss during exhalation. The PARI LC PLUS can be used with all PARI compressors.
Users
Adult and Pediatric patients
What's Included
LC PLUS Reusable Nebulizer, valved mouthpiece, Wing Tip tubing, and Instructions for Use.
Like other plastic components, PARI nebulizers will experience some wear and tear due to frequent use and the cleaning and disinfection process. By replacing your reusable nebulizer every 6 months, you can
Part Number: 022F81
HCPCS Code: A7005
PARI's Breath Enhanced Technology
PARI's reusable nebulizers incorporate breath enhanced technology, which delivers more medication when you breathe in, and wastes less when you breath out, giving patients the best possible treatment.
A YouTube video is loaded here. If you cannot see the video window, it is because you do not allow external content in your settings. For more information, please see our Privacy Policy.
Instructions for use
Instructions for use
English / Spanish
PARI LC PLUS Nebulizer in combination with a 1.2 bar compressor2
| Total Output Rate (TOR) = | 440 mg/min |
| Mass Median Diameter (MMD) = | 3.8 µm |
| Percentage Respirable Fraction (%RF) = | 65 % |
| Average Treatment Time (ATT) = | 6-7 min |
Key Findings:
This study shows that PARI Nebulizers deliver more drug to the lungs in less time compared to other jet nebulizers.
1 Lester, Mary K. Nebulizer Use and Maintenance by Cystic Fibrosis Patients: A Survey Study. Respiratory Care 2004; 49(12): 1504-1508.
2 Tested with a 1.2 bar compressor. Measured with Malvern MasterSizer X at 50% relative humidity, 0.9% NaCl solution, inspiratory flow 20 liters/minute, continuous nebulization, 23° C, fill volume 2.5 ml.
3 Weigand, et al. Using RDDR to Compare Delivery Efficiency of Three Commercially Available Breath-Enhanced Nebulizers with Budesonide. CHEST October 2008
*All registered marks and trademarks belong to their respective companies.
© 2025 PARI Respiratory Equipment, Inc.
